with/without DAC; GHRH analog · Evidence-based safety and harm-reduction overview.
| Also known as | with/without DAC; GHRH analog |
| Category | Peptide |
| Class | Synthetic GHRH analog (30-amino-acid peptide) |
| Route in research | Intramuscular or subcutaneous injection |
| Half-life | Minutes (non-DAC) or hours to days (with DAC formulation) |
| US legal status | Not FDA-approved for human use. Research chemical. WADA-prohibited. |
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), a 30-amino-acid peptide designed to stimulate the anterior pituitary to release growth hormone. The compound is sold in two versions: with DAC (Drug Affinity Complex), which extends half-life, and without DAC. Both are research chemicals only.
CJC-1295 (like all GHRH analogs) binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and secretion of growth hormone. The DAC version is conjugated to an albumin-binding moiety, which extends its plasma half-life from minutes (non-DAC) to hours or days (DAC version). The released GH then acts systemically and triggers hepatic and tissue production of IGF-1.
CJC-1295 was developed in the 2000s as an improved GHRH analog with extended half-life via the DAC technology. Early clinical studies confirmed GH-releasing activity. It did not advance to FDA approval. A related compound (Sermorelin) is an approved, much shorter-acting GHRH analog used in specific diagnostic and therapeutic indications. CJC-1295 became popular in sports and anti-aging circles despite lack of long-term human efficacy or safety data.
Small early human pharmacology studies showed sustained increases in GH and IGF-1 levels over days or weeks depending on formulation. No large long-term efficacy or safety trials in humans exist. Animal models report recovery and body-composition effects, but human clinical benefit is unproven.
In early human studies and case reports, CJC-1295 (with DAC) has been administered by intramuscular or subcutaneous injection at doses in the range of 1-2 micrograms per kilogram, typically once every 3-5 days (due to extended half-life). Non-DAC versions require more frequent dosing. No approved regimen exists.
This is general research/context information, not medical advice or a recommended protocol.
CJC-1295 is often combined with ipamorelin in anecdotal reports, theoretically to provide both GHRH (CJC) and GHSR (ipamorelin) stimulation for synergistic GH release. There is no clinical evidence supporting the safety or efficacy of such combinations.
If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsDAC (Drug Affinity Complex) greatly extends half-life from minutes to hours or days, fundamentally changing how the compound behaves. They are not interchangeable.
No approved human therapeutic product exists. Sermorelin, a shorter-acting GHRH analog, is FDA-approved for specific indications.
Sermorelin is FDA-approved and has a much shorter half-life, requiring daily injection. CJC-1295 (especially with DAC) extends action but is not approved.
Anecdotal reports describe this combination. Theoretically, GHRH (CJC) and GHSR (ipamorelin) stimulation might be synergistic, but there is no clinical evidence or safety data.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.